Prosecution Insights
Prosecution Insights
1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Elixirgen Therapeutics Inc. is currently managing 1 pending office action within its patent portfolio. This single case is assigned to 1 distinct examiner, which centralizes the company's current interactions with the patent office. The busiest examiner for the company is CHESTNUT, BARRY A, who is responsible for 1 pending office action. This workload matches the total pending office actions for the entire portfolio.
Because the distinct examiners count is 1, there is no variation in the personnel reviewing the company's active matters. This concentration suggests that the company's current prosecution strategy is focused on the requirements of a single examiner. The progress of the portfolio is therefore dependent on the specific evaluation provided by this 1 official at the patent office. The data indicates that all active prosecution efforts are concentrated under this single point of contact.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHESTNUT, BARRY A | 1 | 73.5% | +6.4% |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18769203 | TEMPERATURE-BASED TRANSIENT DELIVERY OF NUCLEIC ACIDS AND PROTEINS TO CELLS AND TISSUES | CHESTNUT, BARRY A | — | §103DP | Non-Final OA | — | Pending | Jul 10, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial